journal article
Open Access
Nov 10, 2024
Nanocarriers for intracellular delivery of proteins in biomedical applications: strategies and recent advances
Topics
No keywords indexed for this article. Browse by subject →
References
184
[1]
Roh H, Dorner BG, Ting AY. Cell-type-specific intracellular protein delivery with inactivated Botulinum Neurotoxin. J Am Chem Soc. 2023;145:10220–6.
10.1021/jacs.3c01145
[2]
Xia Y, et al. Filamentous-actin-mimicking nanoplatform for enhanced cytosolic protein delivery. Adv Sci (Weinh). 2024;11:e2305600.
10.1002/advs.202305600
[3]
Mariconti M, et al. Intracellular delivery of functional proteins with DNA-Protein nanogels-lipids complex. J Am Chem Soc. 2024;146:5118–27.
10.1021/jacs.3c08000
[4]
Liu Y, et al. Sarcoma Cells Secrete Hypoxia-Modified Collagen VI to weaken the lung endothelial barrier and promote metastasis. Cancer Res. 2024;84:977–93.
10.1158/0008-5472.can-23-0910
[5]
Subburaj S, Agapito-Tenfen SZ. Establishment of targeted mutagenesis in soybean protoplasts using CRISPR/Cas9 RNP delivery via electro-transfection. Front Plant Sci. 2023;14:1255819.
10.3389/fpls.2023.1255819
[6]
Clift D, et al. A method for the Acute and Rapid Degradation of Endogenous Proteins. Cell. 2017;171:1692–e17061618.
10.1016/j.cell.2017.10.033
[7]
Frangoul H, et al. CRISPR-Cas9 gene editing for Sickle Cell Disease and β-Thalassemia. N Engl J Med. 2021;384:252–60.
10.1056/nejmoa2031054
[8]
Sharma A, et al. CRISPR-Cas9 editing of the HBG1 and HBG2 promoters to treat Sickle Cell Disease. N Engl J Med. 2023;389:820–32.
10.1056/nejmoa2215643
[9]
Philippidis A. CASGEVY makes history as FDA approves first CRISPR/Cas9 genome edited therapy. Hum Gene Ther. 2024;35:1–4.
10.1089/hum.2023.29263.bfs
[10]
Taylor RP, Lindorfer MA. Antibody drug conjugate adverse effects can be understood and addressed based on immune complex clearance mechanisms. Blood. 2024;144:137–144.
10.1182/blood.2024024442
[11]
Jiang G, Huang Z, Yuan Y, Tao K, Feng W. Intracellular delivery of anti-BCR/ABL antibody by PLGA nanoparticles suppresses the oncogenesis of chronic myeloid leukemia cells. J Hematol Oncol. 2021;14:139.
10.1186/s13045-021-01150-x
[12]
An M et al. Engineered virus-like particles for transient delivery of prime editor ribonucleoprotein complexes in vivo. Nat Biotechnol. 2024;42:1526–1537.
10.1038/s41587-023-02078-y
[13]
Kreitz J, et al. Programmable protein delivery with a bacterial contractile injection system. Nature. 2023;616:357–64.
10.1038/s41586-023-05870-7
[14]
Baljon JJ, et al. A Cancer Nanovaccine for Co-delivery of peptide neoantigens and optimized combinations of STING and TLR4 agonists. ACS Nano. 2024;18:6845–62.
10.1021/acsnano.3c04471
[15]
Gao LT, et al. Tough, self-healing and injectable dynamic nanocomposite hydrogel based on gelatin and sodium alginate. Carbohydr Polym. 2024;330:121812.
10.1016/j.carbpol.2024.121812
[16]
He X et al. Hypoxia-Responsive Hydrogen-Bonded Organic Framework-mediated protein delivery for Cancer Therapy. Adv Healthc Mater. 2024;13:e2400747.
10.1002/adhm.202400747
[17]
Wang R, et al. Liposomal enzyme Nanoreactors based on nanoconfinement for efficient Antitumor Therapy. Angew Chem Int Ed Engl. 2023;62:e202308761.
10.1002/anie.202308761
[18]
Wang S, et al. Inhalable hybrid nanovaccines with virus-biomimetic structure boost protective immune responses against SARS-CoV-2 variants. J Nanobiotechnol. 2024;22:76.
10.1186/s12951-024-02345-3
[19]
Sia ZR et al. Adjuvanted nanoliposomes displaying six hemagglutinins and neuraminidases as an influenza virus vaccine. Cell Rep Med. 2024;5:101433.
10.1016/j.xcrm.2024.101433
[20]
Yu S et al. Glucose-driven droplet formation in complexes of a supramolecular peptide and therapeutic protein. Am Chem Soc. 2024;146:7498–7505.
10.1021/jacs.3c13139
[21]
Zhao Z, et al. Endocytosis-independent and Cancer-selective cytosolic protein delivery via reversible tagging with LAT1 substrate. Adv Mater. 2022;34:e2110560.
10.1002/adma.202110560
[22]
Lakkadwala S, Dos Santos Rodrigues B, Sun C, Singh J. Dual functionalized liposomes for efficient co-delivery of anti-cancer chemotherapeutics for the treatment of glioblastoma. J Control Release. 2019;307:247–60.
10.1016/j.jconrel.2019.06.033
[23]
Zhao Y, Jiang H, Yu J, Wang L, Du J. Engineered histidine-rich peptides enhance endosomal escape for antibody-targeted intracellular delivery of functional proteins. Angew Chem Int Ed Engl. 2023;62:e202304692.
10.1002/anie.202304692
[24]
Chirnomas D, Hornberger KR, Crews CM. Protein degraders enter the clinic - a new approach to cancer therapy. Nat Rev Clin Oncol. 2023;20:265–78.
10.1038/s41571-023-00736-3
[25]
Syed AM, et al. Liposome Imaging in optically cleared tissues. Nano Lett. 2020;20:1362–9.
10.1021/acs.nanolett.9b04853
[26]
Gandek TB, van der Koog L, Nagelkerke A. A comparison of Cellular Uptake mechanisms, Delivery Efficacy, and Intracellular Fate between liposomes and Extracellular vesicles. Adv Healthc Mater. 2023;12:e2300319.
10.1002/adhm.202300319
[27]
Patel D, Solanki J, Kher MM, Azagury A. A Review: Surface Engineering of Lipid-Based Drug Delivery Systems. Small, e2401990 (2024).
10.1002/smll.202401990
[28]
Li J, et al. A lava-inspired proteolytic enzyme therapy on cancer with a PEG-based hydrogel enhances tumor distribution and penetration of liposomes. J Nanobiotechnol. 2024;22:216.
10.1186/s12951-024-02468-7
[29]
Wei T et al. Janus Liposozyme for the modulation of redox and immune homeostasis in infected diabetic wounds. Nat Nanotechnol. 2024;19:1178–1189.
10.1038/s41565-024-01660-y
[30]
Rahman MM et al. Chimeric nanobody-decorated liposomes by self-assembly. Nat Nanotechnol. 2024;19:818–824.
10.1038/s41565-024-01620-6
[31]
Wang C et al. Construction strategy of Functionalized liposomes and Multidimensional Application. Small. 2024;20:e2309031.
10.1002/smll.202309031
[32]
Zhu C, et al. Manganese-based multifunctional nanoplatform for dual-modal imaging and synergistic therapy of breast cancer. Acta Biomater. 2022;141:429–39.
10.1016/j.actbio.2022.01.019
[33]
Zhou SH, et al. Multifunctional lipidated protein carrier with a Built-In adjuvant as a universal vaccine platform potently elevates immunogenicity of weak antigens. J Med Chem. 2024;67:6822–38.
10.1021/acs.jmedchem.4c00412
[34]
Pei P, et al. Computer-aided design of Lasso-like self-assembling anticancer peptides with multiple functions for targeted self-delivery and Cancer treatments. ACS Nano. 2022;16:13783–99.
10.1021/acsnano.2c01014
[35]
Zhou S, et al. The predominant Quillaja Saponaria fraction, QS-18, is safe and effective when formulated in a liposomal murine cancer peptide vaccine. J Control Release. 2024;369:687–95.
10.1016/j.jconrel.2024.04.002
[36]
Lopes Chaves L et al. Nanocarriers of antigen proteins for vaccine delivery. Int J Pharm. 2024;659:124162.
10.1016/j.ijpharm.2024.124162
[37]
Santi M, et al. Protein delivery by peptide-based Stealth liposomes: a Biomolecular insight into enzyme replacement therapy. Mol Pharm. 2020;17:4510–21.
10.1021/acs.molpharmaceut.0c00615
[38]
Tomsen-Melero J, et al. Liposomal formulations for treating lysosomal storage disorders. Adv Drug Deliv Rev. 2022;190:114531.
10.1016/j.addr.2022.114531
[39]
Thornton CS et al. Porcine-derived pancreatic enzyme replacement therapy may be linked to chronic hepatitis E virus infection in cystic fibrosis lung transplant recipients. Gut. 2024;73:1702–1711.
10.1136/gutjnl-2023-330602
[40]
Wang TY et al. Devastating the Supply wagons: multifaceted liposomes capable of exhausting tumor to death via Triple Energy Depletion. Small. 2024;20:e2308861.
10.1002/smll.202308861
[41]
Duan QY et al. Reallocating cell respiration substrates for Cancer Therapy using a Metabolism Regulator with an intermembrane-translocatable accessory. Adv Funct Mater 33, (2023).
10.1002/adfm.202213636
[42]
Zhao Z et al. Triggering reactive Oxygen species Field Effect Transistor based on HIF-1α signaling for enhanced chemodynamic therapy. Adv Funct Mater 31, (2021).
10.1002/adfm.202106471
[43]
Yu M, et al. A β-Galactosidase-activated fluorogenic reporter for the detection of gastric Cancer in vivo and in urine. Anal Chem. 2024;96:6390–7.
10.1021/acs.analchem.4c00429
[44]
Antic I, Biancucci M, Zhu Y, Gius DR, Satchell KJF. Site-specific processing of Ras and Rap1 switch I by a MARTX toxin effector domain. Nat Commun. 2015;6:7396.
10.1038/ncomms8396
[45]
Chen X, Zheng Q, Cai W, Sheng J, Wang M. Biodegradable hydrogen-Bonded Organic Framework for Cytosolic protein delivery. ACS Appl Mater Interfaces. 2023;15:54346–52.
10.1021/acsami.3c14450
[46]
Singh S. Antioxidant nanozymes as next-generation therapeutics to free radical-mediated inflammatory diseases: a comprehensive review. Int J Biol Macromol. 2024;260:129374.
10.1016/j.ijbiomac.2024.129374
[47]
Mapuskar KA et al. Mitochondrial superoxide dismutase in Cisplatin-Induced kidney Injury. Antioxid (Basel) 10, (2021).
10.3390/antiox10091329
[48]
Zhang K, et al. A self-disguised nanospy for improving drug delivery efficiency via decreasing drug Protonation. Small. 2023;19:e2300060.
10.1002/smll.202300060
[49]
Costa C, et al. One-step microfluidics production of enzyme-loaded liposomes for the treatment of inflammatory diseases. Colloids Surf B Biointerfaces. 2021;199:111556.
10.1016/j.colsurfb.2020.111556
[50]
Koide H, et al. Easy preparation of a liposome-mediated protein delivery system by freeze-thawing a liposome-protein complex. J Mater Chem B. 2022;10:6768–76.
10.1039/d2tb00271j
Showing 50 of 184 references
Cited By
14
Biocontrol and Nanotechnology Strategies for Postharvest Disease Management in Fruits and Vegetables: A Comprehensive Review
Foods
Habiba Lawal, Mohammed Sani Gaddafi · 2025
Tumor-targeting and redox-responsive photo-cross-linked nanogel derived from multifunctional hyaluronic acid-lipoic acid conjugates for enhanced in vivo protein delivery
International Journal of Biological...
Wei Sun, Moon-Sun Jang · 2025
Metrics
14
Citations
184
References
Details
- Published
- Nov 10, 2024
- Vol/Issue
- 22(1)
- License
- View
Authors
Funding
National Natural Science Foundation of China
Award: 82372108
Basic and Applied Basic Research Foundation of Guangdong Province
Award: 2023A1515012658
Innovation Fund for Outstanding Doctoral Candidates of Peking University Health Science Center
Award: BMU2024BSS001
Cite This Article
Chuanda Zhu, Jing Mu, Ling Liang (2024). Nanocarriers for intracellular delivery of proteins in biomedical applications: strategies and recent advances. Journal of Nanobiotechnology, 22(1). https://doi.org/10.1186/s12951-024-02969-5
Related
You May Also Like
Nano based drug delivery systems: recent developments and future prospects
Jayanta Kumar Patra, Gitishree Das · 2018
5,639 citations
‘Green’ synthesis of metals and their oxide nanoparticles: applications for environmental remediation
Jagpreet Singh, Tanushree Dutta · 2018
2,214 citations
Metal nanoparticles: understanding the mechanisms behind antibacterial activity
Yael N. Slavin, Jason Asnis · 2017
2,212 citations
Nanoparticle classification, physicochemical properties, characterization, and applications: a comprehensive review for biologists
Nadeem Joudeh, Dirk Linke · 2022
1,463 citations
Engineered nanoparticles interacting with cells: size matters
Li Shang, Karin Nienhaus · 2014
1,119 citations